Rare disease is taking his sight. Access to a treatment is hard to get
Judy and Courtney Stecker with their sons, Read (left) and Wheeler (right). Judy and Courtney Stecker CNBC Cures…
BioCryst is profitable. Now it wants to buy more rare disease drugs
CNBC Cures is proudly underwritten by Alexion, AstraZeneca Rare Disease, whose support enables our journalism to elevate stories…
FDA approves Gilead HIV pill Bixlenvo designed to simplify treatment
Gilead Bixlenvo drug Courtesy: Gilead The Food and Drug Administration approved a once-daily HIV pill from Gilead that…
The startup using AI to help build custom treatments for rare diseases
Jacalyn Lee, founder of The DAND Alliance, and her youngest daughter Isla. Jacalyn Lee CNBC Cures is proudly…
Court rules companies can’t import Gilead medications from overseas
Nikos Pekiaridis | Nurphoto | Getty Images A court ruling this week in favor of Gilead Sciences could…
Morgan Stanley says buy these quality stocks. They also pay dividends
As the market broadens out, investors should seek quality stocks, according to Morgan Stanley. On Tuesday , the…
Stocks making the biggest moves premarket: AZN, PEP, CRM, LEVI
Check out the companies making the biggest moves in premarket trading: AstraZeneca — The biopharmaceutical company tumbled 8%…
AstraZeneca CEO says AI is reshaping drug development — and helping boost the odds of success
AstraZeneca CEO Pascal Soriot said artificial intelligence is helping drugmakers develop medicines faster and make smarter decisions throughout…
Reality of Trump’s drug pricing to set in over next 18 months
Vas Narasimhan, chief executive officer of Novartis AG, during an announcement in the Roosevelt Room of the White…
Eli Lilly to acquire cancer drug maker Kelonia in deal worth up to $7B
Eli Lilly will acquire biotech company Kelonia Therapeutics in a deal worth up to $7 billion, the company…
Trump tariffs fall, but trade war impacts linger
A year after President Donald Trump declared his “liberation day” and imposed sweeping tariffs on imports, kicking off…
These 4 charts show the scale of Novo Nordisk’s woes
Novo Nordisk was the first company to make a GLP-1 drug for weight loss and became Europe’s most…